Alector
ALEC
Market cap $182M

1.86 USD

+0.08

4.49%

At close Dec 20, 4:00 PM EST

After hours

1.90

+0.04

2.15%

1 day

4.49%

5 days

-0.53%

1 month

-48.90%

3 months

-67.65%

6 months

-55.61%

Year to date

-76.72%

1 year

-76.40%

5 years

-90.46%

10 years

-89.67%

About: Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Employees: 241

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,809 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

61% more call options, than puts

Call options by funds: $698K | Put options by funds: $433K

0% more funds holding

Funds holding: 159 [Q2] → 159 (+0) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 21

2% less capital invested

Capital invested by funds: $344M [Q2] → $338M (-$5.21M) [Q3]

6% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 50

3.98% less ownership

Funds ownership: 78.53% [Q2] → 74.55% (-3.98%) [Q3]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$3

61%

upside

Avg. target

$11.75

532%

upside

High target

$35

1,782%

upside

4 analyst ratings

2 positive

50%

1 neutral

25%

1 negative

25%

Stifel Paul Matteis 13% 1-year accuracy 2 / 15 met price target	115%upside $4	Hold Downgraded	16 Dec 2024
Morgan Stanley Matthew Harrison 31% 1-year accuracy 5 / 16 met price target	61%upside $3	Underweight Downgraded	26 Nov 2024
BTIG Thomas Shrader 25% 1-year accuracy 1 / 4 met price target	169%upside $5	Buy Maintained	26 Nov 2024
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 105 / 327 met price target	1,782%upside $35	Buy Reiterated	7 Nov 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about ALEC published over the past 30 days

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

Bank of America Securities has downgraded Alector, Inc. ALEC, citing the failure of its AL002 program.

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

Zacks Investment Research

ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study

Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.

ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

On Monday, Alector, Inc. ALEC released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD).

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of Alzheimer's clinical progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR®-SB), and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints. Similarly, there were no significant effects on Alzheimer's fluid biomarkers favoring AL002, and amyloid PET imaging demonstrated no treatment-related reduction of brain amyloid levels. As previously reported, MRI changes resembling amyloid-related imaging abnormalities (ARIA) and infusion-related reactions were observed in INVOKE-2. The instances of ARIA were primarily seen in participants treated with AL002.

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50 million.

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Zacks Investment Research

Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates

Alector (ALEC) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.53 per share a year ago.

Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer's disease (AD), on track for 2024

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:

Alector to Participate in Upcoming Healthcare Conferences

Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript

Alector, Inc. (NASDAQ:ALEC ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Katie Hogan – Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal – Co-Founder and Chief Executive Officer Sara Kenkare-Mitra – President and Head-Research and Development Gary Romano – Chief Medical Officer Marc Grasso – Chief Financial Officer Conference Call Participants Michael Reid – Morgan Stanley Carter Gould – Barclays Tom Shrader – BTIG Sarah Schram – William Blair & Company Ananda Ghosh – H.C. Wainwright & Company Graig Suvannavejh – Mizuho Securities Corinne Jenkins – Goldman Sachs Operator Good afternoon, ladies and gentlemen, and welcome to the Alector Second Quarter and Midyear 2024 Earnings Conference Call.

Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates

Alector (ALEC) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to earnings of $0.02 per share a year ago.

Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates

See News Rankings

Charts implemented using Lightweight Charts™